Enhancing the Therapeutic Potential of RAS-Targeted Inhibitors Through Preclinical Tumor Models
Time: 1:15 pm
day: Conference Day One - Track 2 - Post Lunch
Details:
- Discussing the importance of tumor models in unraveling the complexities of RAS signaling, tumor heterogeneity, and resistance mechanisms to optimize the design and application of RAS-targeted therapies
- Navigating through challenges such as accurate representation of RAS biology, predicting potential off-target effects, and assessing therapeutic responses in preclinical studies
- Discussing innovative approaches such as genetically engineered models to enhance the translational relevance and predictive value of RAS-targeted inhibitor assessments
